Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user is attempting to reformulate a topical gel using PP-405 for hair loss, aiming to enhance its effectiveness with additional compounds. They discuss the potential of PP-405 compared to other treatments like Minoxidil and GT20029, and emphasize the importance of proper formulation for efficacy.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

People are skeptical about the effectiveness and availability of pp405 for hair regrowth, suggesting to use finasteride and minoxidil in the meantime. Some believe pp405 could offer significant regrowth, but it may take years before it's available.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

The user is currently using finasteride and minoxidil and is considering adding microneedling and either RU58841 or Pyrilutamide for potential hair regrowth. They previously used microneedling, RU58841, and oral minoxidil before their hair transplant.

Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation discusses the benefits of combining scalp stem cell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

People are pessimistic about PP405, believed to be Jxl-069, due to doubts about its effectiveness and delivery method. Some think it doesn't work, while others blame the vehicle used for application.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

The user started using RU58841 for hair loss, noticing thicker hair within 30 days but stopped due to breathing issues, which they couldn't directly attribute to RU. They later switched to a topical minoxidil and finasteride mix, which stopped shedding but didn't match RU's quick results.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

The conversation discusses alternatives to Platelet-rich plasma (PRP) for treating androgenic alopecia. Treatments mentioned include Minoxidil, finasteride, and RU58841.

RU58841 is a controversial hair loss treatment with mixed reviews; some users report success, often in combination with other treatments like finasteride or minoxidil, while others experience side effects like chest pain. The treatment's discontinuation is speculated to be due to patent expiration and lack of profitability, despite some users continuing to use it as part of a broader regimen.

People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.

A user expressed satisfaction with a hair and beard transplant at HairofIstanbul using 3200 grafts and PRP, achieving natural-looking results without finasteride or minoxidil. The transformation was praised, though some noted the beard line appeared artificial.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

The conversation is about hair loss treatment progress using finasteride and GHK-CU over six months. Users discuss application methods and share experiences with GHK-CU and AHK.

The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.